Similar positive effects of SGLT-2 inhibitors on liver enzyme and fat levels were also seen in individuals with NAFLD, according to a comprehensive evaluation of seven systematic reviews conducted by Shao et al.45. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.